Robert Tighe

Company: TCR2 Therapeutics

Job title: Vice President - Research

Seminars:

Engineering Strategies to Enhance TRuC-T Cells for the Treatment of Solid Tumors 11:00 am

TRuCs utilize the full signaling capacity of the TCR in an HLA-independent manner Enhancing the function of anti-mesothelin TRuC-T cells with a PD-1xCD28 chimeric switch receptor  Improved expansion and persistence of anti-CD70 TRuC-T cells with an IL-15 enhancementRead more

day: Conference Day Two